Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Vicore Pharma Holding ABNASDAQ: VCRE

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow outflow shrinks to SEK 0

Q2 FY2026 financing cash flow was SEK 0, compared with SEK 15K a year earlier. Trailing-twelve-month financing cash flow was SEK 430.53M. Over 3 fiscal years it compounded at +32.0% a year.

Context

  • Financing cash flow amounted to 11279.6% of revenue in FY2025, up 10516.9 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near SEK 0 or moves back toward the trailing-twelve-month quarterly average of SEK 107.63M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
SEK 0— QoQ
Last fiscal yearDec 2025
SEK 430.54M-48.4% YoY
LTMJun 2026
SEK 430.53M-48.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-48.4%——
3-year CAGR+32.0%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

SEK · from the cash flow

Latest · FY2025
430.54M SEK
Year-over-year change
-48.4%
4-year CAGR
+8.0%

Financing Cash Flow vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -48.4% is the highest of 2, against a peer median of -75.7%.
  • Financing cash flow amounts to 32371.3% of revenue for VCRE, versus a peer median of 9.1%.
VCRE Competitors
Financing Cash Flow for VCRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VCREVicore Pharma Holding ABLTM Jun 2026SEK 430.53M SEK-48.4%+32.0%32371.3%
LQDALiquidia CorporationLTM Jun 2026$40.85M USD-75.7%-2.8%9.1%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —-75.7%-2.8%9.1%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.78M)(290.73M)(321.51M)(194.19M)(452.39M)
Depreciation & Amortization397.75K3.61M3.42M2.24M0
Deferred Income Tax00000
Stock-Based Compensation(172.79K)0000
Change in Working Capital(37.59K)(20.94M)(10.65M)(1.84M)40.81M
Accounts Receivables(37.59K)(1.6M)(4.28M)(35.6M)(3.08M)
Inventory00000
Accounts Payables00000
Other Working Capital0(19.34M)(6.36M)33.77M43.89M
Other Non-Cash Items(231.23M)8.13M79.15M28.84M35.84M
Operating Cash Flow(263.82M)(299.92M)(249.58M)(164.95M)(375.74M)
Capital Expenditures0(3M)000
Acquisitions (Net)00000
Purchases of Investments(76.61M)0(199.04M)(64.81M)(983.95M)
Sales of Investments69.64M77M54.58M213.85M383.45M
Other Investing Activities00000
Investing Cash Flow(6.96M)74M(144.46M)149.04M(600.51M)
Debt Repayment00000
Common Stock Issued316.8M200M500.41M882.14M455.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(237.78K)(12.96M)(29.55M)(48.08M)(24.55M)
Financing Cash Flow316.56M187.04M470.86M834.06M430.54M
Effect of Forex Changes(26.64M)1.48M04.23M(32.16M)
Net Change in Cash2.3M(37.4M)76.82M822.38M(577.85M)
Free Cash Flow(263.82M)(302.92M)(249.58M)(164.95M)(375.74M)

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.